Intelligence · Clinical Development
Pipeline search results
Programs matching “chemotherapy” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 127 pipeline programs matching "chemotherapy" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
UC-0150/1704
Ningbo Cancer Hospital
Patients ≤50 years old with high-risk osteosarcoma (defined as metastatic osteosarcoma at diagnosis or localised osteosarcoma with poor histological response) after pre-operative chemotherapy and surgery of the primary tumour and lung metastases (if applicable).
1 trial -
UC-GIG-2311
Ningbo Cancer Hospital
Fluoropyrimidine (FP)-naive patients with gastrointestinal (GI) cancer and available pre-treatment uracilemia ([U]) starting chemotherapy combining FP (5FU or capecitabine) and oxaliplatin for any indication
1 trial -
cadonilizumab combined with neoadjuvant radiochemotherapy
The First People's Hospital of Lianyungang
Esophageal Squamous Cell Carcinoma
1 trial -
chemotherapy: TS-1, Leucovorin and Gemcitabine
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Pancreatic Adenocarcinoma
1 trial -
cis Platinum/Carboplatin, Pemetrexed Disodium
Shanghai University of Traditional Chinese Medicine
Chemotherapy, Adjuvant
1 trial -
induction chemotherapy and immunotherapy
The First People's Hospital of Lianyungang
ESCC
1 trial -
lurbinectedin for Advanced/Recurrent Endometrial…
The George Institute
Advanced/Recurrent Endometrial Cancer Patients with Disease Progression after Prior Therapy with Platinum-based Chemotherapy
1 trial -
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy
The First People's Hospital of Lianyungang
HER2-positive Breast Cancer
1 trial -
sintilimab+IBI310+chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC Stage II
1 trial -
Concurrent chemotherapy
Sun Yat-sen University
Locally Advanced Lung Carcinoma
1 trial -
Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma (DLBCL)
1 trial -
Dendritic cell therapy combined with surgery in mesothelioma (ENSURE)
Disc Medicine
Adult patients diagnosed with resectable epithelioid MPM, following first-line chemotherapy.
1 trial -
Fostamatinib in combination with chemotherapy (gemcitabine and nab-paclitaxel)
RIGEL PHARMACEUTICALS INC
Pancreatic Ductal Adenocarcinoma (PDAC)
1 trial -
Neoadjuvant chemotherapy
Hospital Authority, Hong Kong
Squamous Cell Carcinoma of Oral Cavity
1 trial -
Nimotuzumab and chemotherapy
Biotech Pharmaceutical Co.,
Non-small Cell Lung Cancer
1 trial -
RESTART; Autologous Transplantation of Adult...
Disc Medicine
Patients operated with curative intend for head and neck cancer with an indication for bilateral postoperative radiotherapy, with or without chemotherapy.
1 trial -
standard chemotherapy medicine combined with Chinese herbs
The First People's Hospital of Lianyungang
Carcinoma, Non-Small-Cell Lung
1 trial -
Camrelizumab + chemotherapy+Thalidomide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Lung Cancer
1 trial -
Cymbalta hard gastro-resistant capsules for chemotherapy-induced neuropathi…
Disc Medicine
chemotherapy-induced neuropathic pain
1 trial -
Kanglaite Injection+Chemotherapy
Xiyuan Hospital of China Academy of Chinese Medical Sciences
NSCLC
1 trial -
SUSTOL
Heron Therapeutics
Chemotherapy-Induced Nausea and Vomiting (CINV)
1 trial -
Sequential Icotinib Plus Chemotherapy
Betta Pharmaceuticals Co.,
EGFR Positive Non-small Cell Lung Cancer
1 trial -
2014CB543202-01
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Chemotherapy-induced Nausea and Vomiting
1 trial -
Chemotherapy drug
The First People's Hospital of Lianyungang
Hepatocellular Carcinoma, Adult
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.